Truist raised the firm’s price target on Insulet (PODD) to $390 from $365 and keeps a Buy rating on the shares. The company posted another strong beat and raise on broad Omnipod 5 strength, the analyst tells investors in a research note. The firm remains confident in Insulet’s prospects to sustain a well-above-average CAGR over the 2024-2028 period, Truist added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: